GSK Bio
NEWS
HES is a rare group of inflammatory disorders that affects approximately 20,000 people around the world.
Merck plunked down $576 million to acquire San Diego-based Calporta to gain access to preclinical TRPML1 agonists that are seen as potential treatments for neurodegenerative disorders such as Alzheimer’s or Parkinson’s.
Ellume Limited is pleased to announce the appointment of Ms Joanne Moss to its Board as an Independent Non-Executive Director and Chair of Audit and Risk, effective immediately.
For BioSpace’s recent Ideal Employer report, life sciences professionals weighed in on the topic.
As the third quarter of 2019 comes to an end, most biopharma companies are reporting their earnings as they head into the final lap for the year. Here’s a look at some of the bigger companies’ reports that came out this week.
MorphoSys AG reported its financial results for the third quarter of 2019.
BioVersys AG announced, US$ 3.94 million in non-dilutive funding from CARB-X, with the possibility of US$ 4.98 million more if certain project milestones are met.
GlaxoSmithKline’s PARP inhibitor Zejula has been approved for wider use in some cancers.
Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies, announces it has appointed Beverley Carr as Chief Business Officer, with effect from 4 November 2019.
JOBS
IN THE PRESS